Th1-CD11c+ B细胞轴与多发性硬化血浆置换疗效相关
该研究分析31例多发性硬化患者血浆置换前后配对血液样本的免疫表型,发现应答者IFN-γ+ Th1细胞频率持续高于无应答者,且治疗前Th1频率预测获益的AUC达0.902;Th1细胞IFNG表达与CD11c+ B细胞频率正相关,后者在血浆置换后下降。研究提示Th1-CD11c+ B细胞轴参与血浆置换治疗应答。
要点
- 治疗前IFN-γ+ Th1细胞频率可预测血浆置换获益,AUC为0.902。
- 应答者Th1细胞频率持续高于无应答者。
- Th1细胞IFNG表达与CD11c+ B细胞频率正相关,后者血浆置换后下降。
核心结论
- Th1细胞-CD11c+ B细胞轴参与多发性硬化患者对血浆置换的治疗应答。
研究设计与样本
- 研究纳入31例多发性硬化患者,分析血浆置换前后配对血液样本的免疫表型,并同步进行临床疗效评估。
主要发现
- 获益患者(应答者)的IFN-γ+ Th1细胞频率持续高于无应答者。
- 血浆置换前Th1细胞频率预测获益的AUC为0.902。
- 血浆置换降低Th1细胞中炎症相关基因表达。
- Th1细胞IFNG表达与CD11c+ B细胞频率正相关。
- 体外实验中CD11c+ B细胞在外源性IFN-γ刺激下较IL-4增加并分泌大量IgG,血浆置换后CD11c+ B细胞及循环免疫球蛋白亚类下降。
临床怎么用
- 治疗前检测IFN-γ+ Th1细胞频率可能辅助筛选血浆置换获益的多发性硬化患者。
局限性
- 样本量较小(31例),结论需更大队列验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Although plasmapheresis is a treatment option for patients with autoimmune neurological diseases, treatment response varies greatly among patients. The main objective of this study was to find out if biological/immune traits correlate with a beneficial response. METHODS: We thoroughly analyzed immune phenotypes in paired blood samples from a cohort of 31 patients with multiple sclerosis before and after plasmapheresis, in parallel with clinical evaluation of treatment response. RESULTS: The frequency of IFN-γ+ Th1 cells was persistently higher in those who obtained benefit from plasmapheresis (responders) than nonresponders. The Th1 cell frequency before plasmapheresis provided a high predictive value for beneficial response, achieving area under the curve (AUC) of 0.902. Plasmapheresis treatment decreased inflammation-related gene expressions in Th1 cells. Meanwhile, IFNG expression in Th1 cells positively correlated with the frequency of CD11c+ B cells, of which a pathogenic role has been suggested in several autoimmune diseases. In line with this, in vitro experiments showed that CD11c+ B cells would increase in response to exogenous IFN-γ compared to IL-4, and secrete high amounts of IgG. B cell receptor analysis indicated that clonal expansion of CD11c+ B cells takes place in patients with multiple sclerosis. Interestingly, CD11c+ B cells, which showed unique gene expression profile, decreased after plasmapheresis treatment along with all the immunoglobulin subsets in the circulation. INTERPRETATION: Taken together, we postulate that Th1 cell - CD11c+ B cell axis is involved in treatment response to plasmapheresis, giving us clues to better understanding of complicated pathogenesis of autoimmune diseases, and getting closer to a personalized therapy. ANN NEUROL 2021;90:595-611.
引用
- Kimura K, Lin Y, Yamaguchi H, et al. Th1 - CD11c+ B Cell Axis Associated with Response to Plasmapheresis in Multiple Sclerosis. Ann Neurol. 2021. PMID: 34424567. doi:10.1002/ana.26202
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。